Last quarter (Q4 2022), Diaceutics's total revenue was £―, a decrease of ― from the same quarter last year. In Q4, Diaceutics's net income was £―. See Diaceutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	-	£ 19.50M	£ 13.94M	£ 12.70M	£ 13.44M	£ 10.37M
Cost of Revenue	-	£ 2.76M	£ 3.21M	£ 3.23M	£ 3.13M	£ 3.57M
Gross Profit	-	£ 16.74M	£ 10.73M	£ 9.46M	£ 10.31M	£ 6.80M
Operating Expense	-	£ 7.51M	£ 10.18M	£ 9.73M	£ 8.22M	£ 5.40M
Operating Income	-	£ 417.00K	£ 550.00K	£ -270.00K	£ 2.09M	£ 1.41M
Net Non Operating Interest Income Expense	-	£ 45.00K	£ 88.00K	£ -24.00K	£ -220.00K	£ -301.58K
Other Income Expense	-	£ 28.00K	-	-	-	-
Pretax Income	-	£ 564.00K	£ 462.00K	£ -682.00K	£ 497.00K	£ 877.26K
Tax Provision	-	£ -160.00K	£ -99.00K	£ -945.00K	£ 99.00K	£ 244.96K
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	-	£ 724.00K	£ 561.00K	£ 263.00K	£ 398.00K	£ 632.31K
Basic EPS	-	£ 0.01	£ 0.01	£ <0.01	£ <0.01	£ <0.01
Diluted EPS	-	£ 0.01	£ 0.01	£ <0.01	£ <0.01	£ <0.01
Basic Average Shares	-	£ 84.15M	£ 83.94M	£ 77.53M	£ 64.07M	£ 69.58M
Diluted Average Shares	-	£ 86.09M	£ 84.94M	£ 77.83M	£ 64.17M	£ 69.58M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	£ 0.74	£ 2.46	£ 42.20
Reported Normalized Diluted E P S	-	-	-	£ 0.74	£ 2.45	£ 40.74
Rent Expense Supplemental	-	-	-	-	-	£ 126.69K
Total Expenses	-	-	£ -13.39M	£ 12.97M	£ 11.35M	£ 8.97M
Net Income From Continuing And Discontinued Operation	-	£ 724.00K	£ 561.00K	£ 263.00K	£ 398.00K	£ 632.31K
Normalized Income	-	£ 404.00K	£ 363.00K	£ 577.28K	£ 1.50M	£ 795.99K
Interest Expense	-	-	-	£ 51.00K	£ 223.00K	£ 301.58K
EBIT	-	£ 684.00K	£ 550.00K	£ -631.00K	£ 720.00K	£ 1.18M
EBITDA	-	£ 3.69M	£ 550.00K	£ 178.00K	£ 1.00M	£ 1.30M

Currency in GBP

Diaceutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing